Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

TENX
Tenax Therapeutics, Inc.
stock NASDAQ

At Close
Apr 10, 2026 3:59:57 PM EDT
14.35USD-4.078%(-0.61)198,197
0.00Bid   0.00Ask   0.00Spread
Pre-market
Apr 8, 2026 8:55:30 AM EDT
15.05USD+0.602%(+0.09)0
After-hours
Apr 9, 2026 4:43:30 PM EDT
14.96USD-0.631%(-0.10)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
04:10PM EST  Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors   GlobeNewswire Inc
Jan 12, 2022
08:37AM EST  Tenax Thearpeutics Reports Was Granted US Patent For Subcutaneous Use Of Levosimendan   Benzinga
08:30AM EST  Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjectswith Any Health Condition   GlobeNewswire Inc
Jan 10, 2022
10:02AM EST  TENX: TNX-103 & TNX-201 Near Ready for Phase III   Benzinga
Jan 4, 2022
09:26AM EST  Abbott (ABT) said that the U.S. Food and Drug Administration has approved new expanded magnetic resonance imaging or MRI compatibility for its Proclaim XR Spinal Cord Stimulation (SCS) System with Octrode leads.   RTTNews
08:50AM EST  Tenax Therapeutics Updates On TNX-102, TNX-103 And TNX-201 Clinical Programs   RTTNews
08:36AM EST  Tenax Therapeutics Receives Notice Of Allowance Of Multiple Patent Claims For TNX-102   Benzinga
08:30AM EST  Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan)   GlobeNewswire Inc
Nov 16, 2021
08:35AM EST  Tenax Therapeutics Q3 EPS $(0.15) Up From $(0.18) YoY   Benzinga
08:35AM EST  Tenax Therapeutics Q3 Loss/shr $0.15 Vs. Loss/shr $0.18 Last Year   RTTNews
08:30AM EST  Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update   Business Wire
Oct 6, 2021
09:09AM EDT  Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company, on Wednesday said the FDA has reviewed and cleared its Investigational New Drug or IND application for a novel formulation of imatinib.   RTTNews
08:35AM EDT  Tenax Therapeutics Announces IND Clearance For Imatinib In Pulmonary Arterial Hypertension   RTTNews
08:34AM EDT  UPDATE: Tenax Says Is On Track To Initiate Single Phase 3 Trial For Pulmonary Arterial Hypertension In Q2'22   Benzinga
08:34AM EDT  Tenax Therapeutics Reports Clearance Of Investigational New Drug Application For Imatinib In Pulmonary Arterial Hypertension   Benzinga
08:30AM EDT  Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)   Business Wire
Sep 28, 2021
08:30AM EDT  Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference   Business Wire
Sep 25, 2021
11:21AM EDT  TENX: Second Quarter Results   Benzinga
Sep 9, 2021
08:00AM EDT  Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference   Business Wire
Aug 17, 2021
08:16AM EDT  Tenax Therapeutics Q2 EPS $(0.10) Beats $(0.13) Estimate   Benzinga
08:07AM EDT  Tenax Therapeutics Q2 Net Loss $1.7 Mln Or $0.10/shr Vs Net Loss Of $2.1 Mln Or $0.23/shr Prior Year   RTTNews
08:00AM EDT  Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update   Business Wire
Aug 12, 2021
12:32PM EDT  Tenax Therapeutics shares were trading higher after the company announced a publication highlighting levosimendan mechanism of action in the Journal of Cardiac Failure.   Benzinga
08:08AM EDT  Tenax Announces Publication Highlighting Novel Levosimendan Mechanism Of Action In Pulmonary Hypertension Patients With Heart Failure And Preserved Ejection Fraction   Benzinga
08:05AM EDT  Tenax Reports Publication Showing Levosimendan Mechanism Of Action In Pulmonary Hypertension Patients With Heart Failure   RTTNews
08:00AM EDT  Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)   Business Wire
Aug 5, 2021
08:00AM EDT  Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)   Business Wire
Jul 7, 2021
08:26AM EDT  Specialty pharmaceutical company Tenax Therapeutics, Inc. (TENX) announced Wednesday the appointment of Christopher Giordano to serve as Chief Executive Officer and a Director of the Company, effective July 14, 2021. He will succeed Anthony DiTonno, who will retire on July 13, 2021 following a successful decade of service with the Company.   RTTNews
08:06AM EDT  Tenax Therapeutics CEO Anthony DiTonno To Retire Effective July 13, 2021   RTTNews
08:03AM EDT  Tenax Therapeutics Announces $10M PIPE Offering Priced At-The-Market Under Nasdaq Rules   Benzinga
08:02AM EDT  Tenax Therapeutics Announces CEO Transition; Christopher Giordano Appointed As CEO   Benzinga
08:00AM EDT  Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules   Business Wire
Jun 22, 2021
04:20PM EDT  Tenax Therapeutics Recent 13D Filing From Stuart Rich Shows 16.84% Stake In Co.   Benzinga
Jun 10, 2021
08:42AM EDT  Tenax Therapeutics Set To Join Russell Microcap Index   Benzinga
May 17, 2021
05:19PM EDT  Tenax Therapeutics Q1 EPS $(1.64) Down From $(0.38) YoY   Benzinga
05:15PM EDT  Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update   Business Wire
Apr 14, 2021
11:51AM EDT  TENX: HELP Results & New Asset to Boot   Benzinga
Apr 9, 2021
08:12AM EDT  Tenax Therapeutics Announces Publication Of Positive Data From Phase 2 HELP Study   RTTNews
08:01AM EDT  Tenax Therapeutics Highlights Publication Of 'Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial'   Benzinga
08:00AM EDT  Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial "   Business Wire
Apr 7, 2021
04:45PM EDT  Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders   Business Wire
Mar 31, 2021
04:45PM EDT  Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update   Business Wire
Mar 4, 2021
08:30AM EST  Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference   Business Wire
Mar 2, 2021
08:19AM EST  Tenax Therapeutics Appoints Four New Members To Its Board   RTTNews
08:15AM EST  Tenax Therapeutics, Inc. Expands Board of Directors   Business Wire
Jan 28, 2021
08:03AM EST  The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO   Benzinga
Jan 20, 2021
07:47AM EST  Tenax Therapeutics Schedules Conference Call To Discuss Its Transformative Acquisition Of PH Precision Med For Jan. 21, 2021   Benzinga
07:45AM EST  Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med   Business Wire
Jan 19, 2021
07:56AM EST  Tenax Therapeutics Announces Acquisition Of PH Precision Med   RTTNews
07:47AM EST  Tenax Therapeutics Announces Acquisition Of PH Precision Med For ~12.1M Unregistered Shares, Securities Convertible Into Stock   Benzinga
07:46AM EST  Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med   Business Wire
Dec 30, 2020
08:16AM EST  The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data   Benzinga
Dec 29, 2020
10:29AM EST  Shares of nano-cap company Tenax Therapeutics Inc. (TENX) more than doubled on Tuesday despite no-stock related news to drive the shares.   RTTNews
10:12AM EST  Benzinga's Top Upgrades, Downgrades For December 29, 2020   Benzinga
06:11AM EST  HC Wainwright & Co. Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $5   Benzinga
Nov 16, 2020
04:45PM EST  Tenax Therapeutics Q3 EPS $(0.18) Up From $(0.33) YoY   Benzinga
04:45PM EST  Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update   Business Wire
Nov 10, 2020
08:42AM EST  Tenax Therapeutics Highlights Presentation Of 24-Hour HELP Study Results At American Heart Association Meeting Nov. 13   Benzinga
08:36AM EST  Tenax Therapeutics Announces Presentation Of 24-Hour HELP Study Results At AHA Scientific Sessions 2020   RTTNews
08:30AM EST  Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020   Business Wire
Nov 6, 2020
08:30AM EST  Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results   Business Wire
Nov 2, 2020
01:24PM EST  CORRECTION: Tenax Therapeutics Ticker Is TENX   Benzinga
Oct 15, 2020
08:31AM EDT  Tenax Therapeutics Gains North American Rights To Oral Levosimendan Through Expanded License Agreement With Orion Corporation   Benzinga
Oct 2, 2020
08:33AM EDT  Tenax Therapeutics To Present Clinical Trial Presentation Of Phase 2 HELP Study At Heart Failure Society Of America (HFSA) Virtual Annual Scientific Meeting Oct. 3   Benzinga
08:30AM EDT  Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting   Business Wire
Sep 1, 2020
10:44AM EDT  Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference   Business Wire
Aug 31, 2020
08:33AM EDT  Tenax Announces That Late-Breaking Results From HELP Study Have Been Accepted For Presentation At Heart Failure Society Of America (HFSA) Annual Scientific Meeting   Benzinga
08:30AM EDT  Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting   Business Wire
Aug 17, 2020
09:33AM EDT  Tenax Therapeutics Q2 Net Loss $2.1 Mln Or $0.23/Shr Vs Loss $1.8 Mln Or $0.28/Shr Last Year   RTTNews
08:08AM EDT  Tenax Therapeutics Q2 EPS $(0.23) Up From $(0.28) YoY   Benzinga
08:00AM EDT  Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update   Business Wire
Jul 20, 2020
08:45AM EDT  Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD   Business Wire
05:11AM EDT  80 Biggest Movers From Friday   Benzinga
Jul 16, 2020
04:26PM EDT  Armistice Capital Reports 19.99% Active Stake In Tenax Therapeutics   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC